**Abstract**

**Introduction:** Guidelines specify long-acting injectable (LAI) antipsychotic use earlier in schizophrenia because it may delay functional deterioration. Paliperidone palmitate (PP) LAI therapy in patients with schizophrenia was evaluated by duration of illness.

**Methods:** Post hoc analysis of a randomized, double-blind (DB), parallel-group, multicenter, noninferiority study (NCT01515423). Subjects with schizophrenia were treated with PP once-monthly (PP1M) in a 17-week open-label (OL) phase. Upon meeting clinical stabilization criteria, they were randomized 1:1 to PP1M or PP once-every-3-months (PP3M) in a 48-week relapse-prevention phase. Subjects were evaluated based on duration of illness (≤5, 6--10, and \>10 years since diagnosis); PP1M and PP3M results were combined. Positive and Negative Syndrome Scale (PANSS) and Personal and Social Performance (PSP) scale scores and functional remission rates (PSP \>70 from week 13 \[OL\] and during DB phase for ≥6 months) were analyzed. No adjustment was made for multiplicity.

**Results:** 532, 337, and 558 subjects diagnosed with schizophrenia ≤5, 6--10, and \>10 years ago, respectively, entered OL phase. Of these, 379 (71.2%), 235 (69.7%), and 380 (68.1%) met clinical stabilization criteria and entered DB phase. Significant differences were observed in the ≤5 and 6--10 groups versus the \>10 group from DB baseline to DB endpoint for PANSS and PSP total scores (*P*\<0.03 for all). More patients achieved functional remission in the ≤5 (26.4%) and 6--10 (30.2%) groups versus the \>10 group (18.6%).

**Conclusion:** Improvements were observed with PP LAIs in all subgroups, with greater improvements among patients earlier in the illness (\<5 or 5--10 years) compared to those with more chronic illness (\>10 years).
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